ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Dermatomyositis and polymyositis
Clinical presentation, autoantibodies, and pathogenesis
Andrew L. Mammen,
Andrew L. Mammen
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Search for more papers by this authorAndrew L. Mammen,
Andrew L. Mammen
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Search for more papers by this authorAddress for correspondence: Andrew L. Mammen, MD, PhD, Johns Hopkins University School of Medicine, Dept. of Neurology, Johns Hopkins Bayview, Johns Hopkins Myositis Center, Mason F. Lord Building Center Tower, Suite 4100, Baltimore, MD 21224. Voice: 410-550-6962; fax: 410-550-3542. [email protected]
Abstract
Dermatomyositis (DM) and polymyositis (PM) are autoimmune myopathies characterized clinically by proximal muscle weakness, muscle inflammation, extramuscular manifestations, and frequently, the presence of autoantibodies. Although there is some overlap, DM and PM are separate diseases with different pathophysiological mechanisms. Furthermore, unique clinical phenotypes are associated with each of the myositis-specific autoantibodies (MSAs) associated with these disorders. This review will focus on the clinical features, pathology, and immunogenetics of PM and DM with an emphasis on the importance of autoantibodies in defining unique phenotypes and, perhaps, as clues to help elucidate the mechanisms of disease.
References
- 1
Bohan, A. &
J.B. Peter. 1975. Polymyositis and dermatomyositis (first of two parts).
N. Engl. J. Med.
292: 344–347.
- 2
Bohan, A. &
J.B. Peter. 1975. Polymyositis and dermatomyositis (second of two parts).
N. Engl. J. Med.
292: 403–407.
- 3
Dalakas, M.C. &
R. Hohlfeld. 2003. Polymyositis and dermatomyositis.
Lancet
362: 971–982.
- 4
Karpati, G. &
E.K. O’Ferrall. 2009. Sporadic inclusion body myositis: pathogenic considerations.
Ann. Neurol.
65: 7–11.
- 5
Wagner, E.
1863. Fall einer seltnen Muskelkrankheit.
Dtsch. Arch. Heilk.
4: 282.
- 6
Hepp, P.
1887. Ueber einen Fall von acuter parenchymatoser Myositis, welche Geschwulste bildete und Fluctuation vortauschte.
Klin. Wochenschr.
24: 389.
- 7
Unverricht, H.
1887. Polymyositis acuta progressive.
Z. Klin. Med.
12: 553.
- 8
Unverricht, H.
1891. Dermatomyositis acuta.
Dtsch. Med. Wochenschr.
17: 41.
- 9
Eaton, L.M.
1954. The perspective of neurology in regard to polymyositis; a study of 41 cases.
Neurology
4: 245–263.
- 10
Walton, J.M. &
R.D. Adams. 1958. Polymyositis. E & S Livingstone.
Edinburgh
.
- 11
Rowland, L.P.
1958. Muscular dystrophies, polymyositis, and other myopathies.
J. Chronic Dis.
8: 510–535.
- 12
Pearson, C.M. &
A.S. Rose. 1960. Myositis: the inflammatory disorders of muscle.
Res. Publ. Assoc. Res. Nerv. Ment. Dis.
38: 422.
- 13
Emslie-Smith, A.M. &
A.G. Engel. 1990. Microvascular changes in early and advanced dermatomyositis: a quantitative study.
Ann. Neurol.
27: 343–356.
- 14
Kissel, J.T.,
J.R. Mendell &
K.W. Rammohan. 1986. Microvascular deposition of complement membrane attack complex in dermatomyositis.
N. Engl. J. Med.
314: 329–334.
- 15
Kissel, J.T.,
R.K. Halterman,
K.W. Rammohan,
et al
. 1991. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis.
Arch. Neurol.
48: 26–30.
- 16
Nagaraju, K.,
L.G. Rider,
C. Fan,
et al
. 2006. Endothelial cell activation and neovascularization are prominent in dermatomyositis.
J. Autoimmune Dis.
3: 2.
- 17
Grundtman, C.,
E. Tham,
A.K. Ulfgren,
et al
. 2008. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis.
Arthritis Rheum.
58: 3224–3238.
- 18
Karpati, G.,
S. Carpenter,
C. Melmed,
et al
. 1974. Experimental ischemic myopathy.
J. Neurol. Sci.
23: 129–161.
- 19
Hathaway, P.W.,
W.K. Engel &
H. Zellweger. 1970. Experimental myopathy after microarterial embolization; comparison with childhood x-linked pseudohypertrophic muscular dystrophy.
Arch. Neurol.
22: 365–378.
- 20
Arahata, K. &
A.G. Engel. 1984. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells.
Ann. Neurol.
16: 193–208.
- 21
Greenberg, S.A.,
J.L. Pinkus,
G.S. Pinkus,
et al
. 2005. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis.
Ann. Neurol.
57: 664–678.
- 22
Siegal, F.P.,
N. Kadowaki,
M. Shodell,
et al
. 1999. The nature of the principal type 1 interferon-producing cells in human blood.
Science
284: 1835–1837.
- 23
Walsh, R.J.,
S.W. Kong,
Y. Yao,
et al
. 2007. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.
Arthritis Rheum.
56: 3784–3792.
- 24
Baechler, E.C.,
J.W. Bauer,
C.A. Slattery,
et al
. 2007. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity.
Mol. Med.
13: 59–68.
- 25
Arahata, K. &
A.G. Engel. 1986. Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury.
Ann. Neurol.
19: 112–125.
- 26
Dalakas, M.C.
1991. Polymyositis, dermatomyositis and inclusion-body myositis.
N. Engl. J. Med.
325: 1487–1498.
- 27
Appleyard, S.T.,
M.J. Dunn,
V. Dubowitz,
et al
. 1985. Increased expression of HLA ABC class I antigens by muscle fibres in Duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders.
Lancet
1: 361–363.
- 28
Karpati, G.,
Y. Pouliot &
S. Carpenter. 1988. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles.
Ann. Neurol.
23: 64–72.
- 29
Nagaraju, K.,
N. Raben,
L. Loeffler,
et al
. 2000. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies.
Proc. Natl. Acad. Sci. USA
97: 9209–9214.
- 30
Nagaraju, K.,
L. Casciola-Rosen,
I. Lundberg,
et al
. 2005. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction.
Arthritis Rheum.
52: 1824–1835.
- 31
Goebels, N.,
D. Michaelis,
M. Engelhardt,
et al
. 1996. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis.
J. Clin. Invest.
97: 2905–2910.
- 32
Behrens, L.,
A. Bender,
M.A. Johnson,
et al
. 1997. Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells.
Brain
120(Pt 6): 929–938.
- 33
Schneider, C.,
R. Gold,
M.C. Dalakas,
et al
. 1996. MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis.
J. Neuropathol. Exp. Neurol.
55: 1205–1209.
- 34
Vattemi, G.,
P. Tonin,
M. Filosto,
et al
. 2000. T-cell anti-apoptotic mechanisms in inflammatory myopathies.
J. Neuroimmunol.
111: 146–151.
- 35
Nagaraju, K.,
L. Casciola-Rosen,
A. Rosen,
et al
. 2000. The inhibition of apoptosis in myositis and in normal muscle cells.
J. Immunol.
164: 5459–5465.
- 36
Lundberg, I.E. &
C. Grundtman. 2008. Developments in the scientific and clinical understanding of inflammatory myopathies.
Arthritis Res. Ther.
10: 220.
- 37
Lundberg, I.,
A.K. Ulfgren,
P. Nyberg,
et al
. 1997. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies.
Arthritis Rheum.
40: 865–874.
- 38
Page, G.,
G. Chevrel &
P. Miossec. 2004. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells.
Arthritis Rheum.
50: 199–208.
- 39
Lundberg, I.,
J.M. Brengman &
A.G. Engel. 1995. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls.
J. Neuroimmunol.
63: 9–16.
- 40
Tews, D.S. &
H.H. Goebel. 1996. Cytokine expression profile in idiopathic inflammatory myopathies.
J. Neuropathol. Exp. Neurol.
55: 342–347.
- 41
Lepidi, H.,
V. Frances,
D. Figarella-Branger,
et al
. 1998. Local expression of cytokines in idiopathic inflammatory myopathies.
Neuropathol. Appl. Neurobiol.
24: 73–79.
- 42
Greenberg, S.A.,
E.M. Bradshaw,
J.L. Pinkus,
et al
. 2005. Plasma cells in muscle in inclusion body myositis and polymyositis.
Neurology
65: 1782–1787.
- 43
Callen, J.P.
2000. Dermatomyositis. Lancet
355: 53–57.
- 44
Dugan, E.M.,
A.M. Huber,
F.W. Miller,
et al
. 2009. Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies.
Dermatol. Online J.
15: 2.
- 45
Dugan, E.M.,
A.M. Huber,
F.W. Miller,
et al
. 2009. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies.
Dermatol. Online J.
15: 1.
- 46
Bridges, B.F.
1991. The rashes of dermatomyositis in a black patient.
Am. J. Med.
91: 661–662.
- 47
Keil, H.
1942. The manifestations in the skin and mucous membranes in dermatomyositis, with special reference to the differential diagnosis from systemic lupus erythematosus.
Ann. Intern. Med.
16: 828.
- 48
Ghali, F.E.,
L.D. Stein,
J.D. Fine,
et al
. 1999. Gingival telangiectases: an underappreciated physical sign of juvenile dermatomyositis.
Arch. Dermatol.
135: 1370–1374.
- 49
Cheong, W.K.,
G.R. Hughes,
P.G. Norris,
et al
. 1994. Cutaneous photosensitivity in dermatomyositis.
Br. J. Dermatol.
131: 205–208.
- 50
Dourmishev, L.,
H. Meffert &
H. Piazena. 2004. Dermatomyositis: comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects.
Photodermatol. Photoimmunol. Photomed.
20: 230–234.
- 51
Euwer, R.L. &
R.D. Sontheimer. 1991. Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature.
J. Am. Acad. Dermatol.
24: 959–966.
- 52
Rockerbie, N.R.,
T.Y. Woo,
J.P. Callen,
et al
. 1989. Cutaneous changes of dermatomyositis precede muscle weakness.
J. Am. Acad. Dermatol.
20: 629–632.
- 53
Stonecipher, M.R.,
J.L. Jorizzo,
W.L. White,
et al
. 1993. Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: dermatomyositis sine myositis?
J. Am. Acad. Dermatol.
28: 951–956.
- 54
Cosnes, A.,
F. Amaudric,
R. Gherardi,
et al
. 1995. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids.
Arch. Dermatol.
131: 1381–1385.
- 55
Cao, H.,
T.N. Parikh &
J. Zheng. 2009. Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis.
Clin. Rheumatol.
28: 979–984.
- 56
Crowson, A.N.,
C.M. Magro &
M.C. Mihm Jr. 2008. Interface dermatitis.
Arch. Pathol. Lab. Med.
132: 652–666.
- 57
Dourmishev, L.A. &
U. Wollina. 2006. Dermatomyositis: immunopathologic study of skin lesions.
Acta Dermatovenerol. Alp. Panonica Adriat.
15: 45–51.
- 58
Mascaro, J.M., Jr., G. Hausmann,
C. Herrero,
et al
. 1995. Membrane attack complex deposits in cutaneous lesions of dermatomyositis.
Arch. Dermatol.
131: 1386–1392.
- 59
Crowson, A.N. &
C.M. Magro. 1996. The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis.
Hum. Pathol.
27: 15–19.
- 60
Hengstman, G.J.,
L. van Brenk,
W.T. Vree Egberts,
et al
. 2005. High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders.
J. Neurol.
252: 534–537.
- 61
Nishikai, M. &
M. Reichlin. 1980. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system.
Arthritis Rheum.
23: 881–888.
- 62
Yoshida, S.,
M. Akizuki,
T. Mimori,
et al
. 1983. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis.
Arthritis Rheum.
26: 604–611.
- 63
Marguerie, C.,
C.C. Bunn,
H.L. Beynon,
et al
. 1990. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes.
Q. J. Med.
77: 1019–1038.
- 64
Mathews, M.B.,
M. Reichlin,
G.R. Hughes,
et al
. 1984. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody.
J. Exp. Med.
160: 420–434.
- 65
Bunn, C.C.,
R.M. Bernstein &
M.B. Mathews. 1986. Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis.
J. Exp. Med.
163: 1281–1291.
- 66
Targoff, I.N.
1990. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis.
J. Immunol.
144: 1737–1743.
- 67
Hirakata, M.,
A. Suwa,
S. Nagai,
et al
. 1999. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease.
J. Immunol.
162: 2315–2320.
- 68
Hashish, L.,
E.P. Trieu,
P. Sadanandan,
et al
. 2005. Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with anti-synthetase syndrome (abstract).
Arthritis Rheum.
52: S312.
- 69
Betteridge, Z.,
H. Gunawardena,
J. North,
et al
. 2007. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia.
Rheumatology (Oxford)
46: 1005–1008.
- 70
Hirakata, M.
2005. Autoantibodies to aminoacyl-tRNA synthetases.
Intern. Med.
44: 527–528.
- 71
Targoff, I.N.
2002. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies.
Rheum. Dis. Clin. North Am.
28: 859–890, viii.
- 72
Kalluri, M.,
S.A. Sahn,
C.V. Oddis,
et al
. 2009. Clinical profile of anti-PL-12 autoantibody: Cohort study and review of the literature.
Chest
135: 1550–1556.
- 73
Arsura, E.L. &
A.S. Greenberg. 1988. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis.
Semin. Arthritis Rheum.
18: 29–37.
- 74
Marie, I.,
E. Hachulla,
P. Cherin,
et al
. 2002. Interstitial lung disease in polymyositis and dermatomyositis.
Arthritis Rheum.
47: 614–622.
- 75
Douglas, W.W.,
H.D. Tazelaar,
T.E. Hartman,
et al
. 2001. Polymyositis-dermatomyositis-associated interstitial lung disease.
Am. J. Respir. Crit. Care Med.
164: 1182–1185.
- 76
Friedman, A.W.,
I.N. Targoff &
F.C. Arnett. 1996. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis.
Semin. Arthritis Rheum.
26: 459–467.
- 77
Yoshifuji, H.,
T. Fujii,
S. Kobayashi,
et al
. 2006. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies.
Autoimmunity
39: 233–241.
- 78
Targoff, I.N.
2008. Autoantibodies and their significance in myositis.
Curr. Rheumatol. Rep.
10: 333–340.
- 79
Fathi, M.,
J. Vikgren,
M. Boijsen,
et al
. 2008. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology.
Arthritis Rheum.
59: 677–685.
- 80
Klein, R.Q.,
V. Teal,
L. Taylor,
et al
. 2007. Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center.
J. Am. Acad. Dermatol.
57: 937–943.
- 81
Selva-O’Callaghan, A.,
M. Labrador-Horrillo,
R. Solans-Laque,
et al
. 2006. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy.
Arthritis Rheum.
55: 791–798.
- 82
Spath, M.,
M. Schroder,
B. Schlotter-Weigel,
et al
. 2004. The long-term outcome of anti-Jo-1-positive inflammatory myopathies.
J. Neurol.
251: 859–864.
- 83
Lundberg, I.E. &
C.J. Forbess. 2008. Mortality in idiopathic inflammatory myopathies.
Clin. Exp. Rheumatol.
26: S109–S114.
- 84
Medsger, T.A., Jr,
H. Robinson &
A.T. Masi. 1971. Factors affecting survivorship in polymyositis. A life-table study of 124 patients.
Arthritis Rheum.
14: 249–258.
- 85
Marie, I.,
E. Hachulla,
P.Y. Hatron,
et al
. 2001. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis.
J. Rheumatol.
28: 2230–2237.
- 86
Sultan, S.M.,
Y. Ioannou,
K. Moss,
et al
. 2002. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality.
Rheumatology (Oxford)
41: 22–26.
- 87
Danko, K.,
A. Ponyi,
T. Constantin,
et al
. 2004. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases.
Medicine (Baltimore)
83: 35–42.
- 88
Airio, A.,
H. Kautiainen &
M. Hakala. 2006. Prognosis and mortality of polymyositis and dermatomyositis patients.
Clin. Rheumatol.
25: 234–239.
- 89
Torres, C.,
R. Belmonte,
L. Carmona,
et al
. 2006. Survival, mortality and causes of death in inflammatory myopathies.
Autoimmunity
39: 205–215.
- 90
Raben, N.,
R. Nichols,
J. Dohlman,
et al
. 1994. A motif in human histidyl-tRNA synthetase which is shared among several aminoacyl-tRNA synthetases is a coiled-coil that is essential for enzymatic activity and contains the major autoantigenic epitope.
J. Biol. Chem.
269: 24277–24283.
- 91
Martin, A.,
M.J. Shulman &
F.W. Tsui. 1995. Epitope studies indicate that histidyl-tRNA synthetase is a stimulating antigen in idiopathic myositis.
FASEB J.
9: 1226–1233.
- 92
Miller, F.W.,
S.A. Twitty,
T. Biswas,
et al
. 1990. Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies.
J. Clin. Invest.
85: 468–475.
- 93
Miller, F.W.,
K.A. Waite,
T. Biswas,
et al
. 1990. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity.
Proc. Natl. Acad. Sci. USA
87: 9933–9937.
- 94
Bernstein, R.M.,
S.H. Morgan,
J. Chapman,
et al
. 1984. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease.
Br. Med. J. (Clin. Res. Ed.)
289: 151–152.
- 95
Stone, K.B.,
C.V. Oddis,
N. Fertig,
et al
. 2007. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy.
Arthritis Rheum.
56: 3125–3131.
- 96
Levine, S.M.,
N. Raben,
D. Xie,
et al
. 2007. Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis.
Arthritis Rheum.
56: 2729–2739.
- 97
Casciola-Rosen, L.,
F. Andrade,
D. Ulanet,
et al
. 1999. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity.
J. Exp. Med.
190: 815–826.
- 98
Katsumata, Y.,
W.M. Ridgway,
T. Oriss,
et al
. 2007. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation.
J. Autoimmun.
29: 174–186.
- 99
Howard, O.M.,
H.F. Dong,
D. Yang,
et al
. 2002. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells.
J. Exp. Med.
196: 781–791.
- 100
Reichlin, M. &
M. Mattioli. 1976. Description of a serological reaction characteristic of polymyositis.
Clin. Immunol. Immunopathol.
5: 12–20.
- 101
Ghirardello, A.,
S. Zampieri,
L. Iaccarino,
et al
. 2005. Anti-Mi-2 antibodies.
Autoimmunity
38: 79–83.
- 102
Targoff, I.N. &
M. Reichlin. 1985. The association between Mi-2 antibodies and dermatomyositis.
Arthritis Rheum.
28: 796–803.
- 103
Targoff, I.N.
2006. Myositis specific autoantibodies.
Curr. Rheumatol. Rep.
8: 196–203.
- 104
Love, L.A.,
R.L. Leff,
D.D. Fraser,
et al
. 1991. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.
Medicine (Baltimore)
70: 360–374.
- 105
Arnett, F.C.,
I.N. Targoff,
T. Mimori,
et al
. 1996. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis.
Arthritis Rheum.
39: 1507–1518.
- 106
Mierau, R.,
T. Dick,
P. Bartz-Bazzanella,
et al
. 1996. Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain.
Arthritis Rheum.
39: 868–876.
- 107
Hausmanowa-Petrusewicz, I.,
E. Kowalska-Oledzka,
F.W. Miller,
et al
. 1997. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies.
Arthritis Rheum.
40: 1257–1266.
- 108
Hengstman, G.J.,
W.T. Vree Egberts,
H.P. Seelig,
et al
. 2006. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen.
Ann. Rheum. Dis.
65: 242–245.
- 109
Brouwer, R.,
G.J. Hengstman,
W. Vree Egberts,
et al
. 2001. Autoantibody profiles in the sera of European patients with myositis.
Ann. Rheum. Dis.
60: 116–123.
- 110
Hengstman, G.J.,
R. Brouwer,
W.T. Egberts,
et al
. 2002. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies.
J. Neurol.
249: 69–75.
- 111
Seelig, H.P.,
I. Moosbrugger,
H. Ehrfeld,
et al
. 1995. The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation.
Arthritis Rheum.
38: 1389–1399.
- 112
Seelig, H.P.,
M. Renz,
I.N. Targoff,
et al
. 1996. Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen.
Arthritis Rheum.
39: 1769–1771.
- 113
Ge Q.,
D.S. Nilasena,
C.A. O’Brien,
et al
. 1995. Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen.
J. Clin. Invest.
96: 1730–1737.
- 114
Nilasena, D.S.,
E.P. Trieu &
I.N. Targoff. 1995. Analysis of the Mi-2 autoantigen of dermatomyositis.
Arthritis Rheum.
38: 123–128.
- 115
Zhang, Y.,
G. LeRoy,
H.P. Seelig,
et al
. 1998. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities.
Cell
95: 279–289.
- 116
Wang, H.B. &
Y. Zhang. 2001. Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor.
Nucleic Acids Res.
29: 2517–2521.
- 117
Shimono, Y.,
H. Murakami,
K. Kawai,
et al
. 2003. Mi-2 beta associates with BRG1 and RET finger protein at the distinct regions with transcriptional activating and repressing abilities.
J. Biol. Chem.
278: 51638–51645.
- 118
Ahringer, J.
2000. NuRD and SIN3 histone deacetylase complexes in development.
Trends Genet.
16: 351–356.
- 119
Kehle, J.,
D. Beuchle,
S. Treuheit,
et al
. 1998. dMi-2, a hunchback-interacting protein that functions in polycomb repression.
Science
282: 1897–1900.
- 120
Solari, F. &
J. Ahringer. 2000. NURD-complex genes antagonise Ras-induced vulval development in Caenorhabditis elegans.
Curr. Biol.
10: 223–226.
- 121
Kashiwagi, M.,
B.A. Morgan &
K. Georgopoulos. 2007. The chromatin remodeler Mi-2beta is required for establishment of the basal epidermis and normal differentiation of its progeny.
Development
134: 1571–1582.
- 122
Hengstman, G.J.,
W.T. Vree Egberts,
H.P. Seelig,
et al
. 2006. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen.
Ann. Rheum. Dis.
65: 242–245.
- 123
Roux, S.,
H.P. Seelig &
O. Meyer. 1998. Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis.
J. Rheumatol.
25: 395–396.
- 124
Hengstman, G.J.,
W.J. van Venrooij,
J. Vencovsky,
et al
. 2000. The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient.
Ann. Rheum. Dis.
59: 141–142.
- 125
Okada, S.,
E. Weatherhead,
I.N. Targoff,
et al
. 2003. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease.
Arthritis Rheum.
48: 2285–2293.
- 126
Burd, C.J.,
H.K. Kinyamu,
F.W. Miller,
et al
. 2008. UV radiation regulates Mi-2 through protein translation and stability.
J. Biol. Chem.
283: 34976–34982.
- 127
Casciola-Rosen, L.,
K. Nagaraju,
P. Plotz,
et al
. 2005. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy.
J. Exp. Med.
201: 591–601.
- 128
Reeves, W.H.,
S.K. Nigam &
G. Blobel. 1986. Human autoantibodies reactive with the signal-recognition particle.
Proc. Natl. Acad. Sci. USA
83: 9507–9511.
- 129
Satoh, T.,
T. Okano,
T. Matsui,
et al
. 2005. Novel autoantibodies against 7SL RNA in patients with polymyositis/dermatomyositis.
J. Rheumatol.
32: 1727–1733.
- 130
Targoff, I.N.,
A.E. Johnson &
F.W. Miller. 1990. Antibody to signal recognition particle in polymyositis.
Arthritis Rheum.
33: 1361–1370.
- 131
Miller, T.,
M.T. Al-Lozi,
G. Lopate,
et al
. 2002. Myopathy with antibodies to the signal recognition particle: clinical and pathological features.
J. Neurol. Neurosurg. Psychiatry
73: 420–428.
- 132
Kao, A.H.,
D. Lacomis,
M. Lucas,
et al
. 2004. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy.
Arthritis Rheum.
50: 209–215.
- 133
Hengstman, G.J.,
H.J. ter Laak,
W.T. Vree Egberts,
et al
. 2006. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy.
Ann. Rheum. Dis.
65: 1635–1638.
- 134
Kaji, K.,
M. Fujimoto,
M. Hasegawa,
et al
. 2007. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy.
Rheumatology (Oxford)
46: 25–28.
- 135
Targoff, I.N.,
G. Mamyrova,
E.P. Trieu,
et al
. 2006. A novel autoantibody to a 155-kd protein is associated with dermatomyositis.
Arthritis Rheum.
54: 3682–3689.
- 136
Gunawardena, H.,
L.R. Wedderburn,
J. North,
et al
. 2008. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis.
Rheumatology (Oxford)
47: 324–328.
- 137
O’Hanlon, T.P.,
L.G. Rider,
A. Schiffenbauer,
et al
. 2008. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies.
Arthritis Rheum.
58: 3239–3246.
- 138
O’Hanlon, T.P.,
D.M. Carrick,
F.C. Arnett,
et al
. 2005. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians.
Medicine (Baltimore)
84: 338–349.
- 139
O’Hanlon, T.P.,
D.M. Carrick,
I.N. Targoff,
et al
. 2006. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies.
Medicine (Baltimore)
85: 111–127.
- 140
Hassan, A.B.,
L. Nikitina-Zake,
C.B. Sanjeevi,
et al
. 2004. Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1*03) with polymyositis and dermatomyositis.
Arthritis Rheum.
50: 1013–1015.
- 141
Chinoy, H.,
F. Salway,
S. John,
et al
. 2007. Tumour necrosis factor-alpha single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies.
Rheumatology (Oxford)
46: 1411–1416.
- 142
Pachman, L.M.,
M.R. Liotta-Davis,
D.K. Hong,
et al
. 2000. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications.
Arthritis Rheum.
43: 2368–2377.
- 143
Mamyrova, G.,
T.P. O’Hanlon,
L. Sillers,
et al
. 2008. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis.
Arthritis Rheum.
58: 3941–3950.
- 144
Werth, V.P.,
J.P. Callen,
G. Ang,
et al
. 2002. Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis.
J. Invest. Dermatol.
119: 617–620.
- 145
Lutz, J.,
K.G. Huwiler,
T. Fedczyna,
et al
. 2002. Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis.
Clin. Immunol.
103: 260–263.
- 146
Pachman, L.M.,
T.O. Fedczyna,
T.S. Lechman,
et al
. 2001. Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity.
Curr. Rheumatol. Rep.
3: 379–386.
- 147
Werth, V.P.,
W. Zhang,
K. Dortzbach,
et al
. 2000. Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription.
J. Invest. Dermatol.
115: 726–730.
- 148
Garlepp, M.J.
1993. Immunogenetics of inflammatory myopathies.
Baillieres Clin. Neurol.
2: 579–597.
- 149
Chinoy, H.,
F. Salway,
S. John,
et al
. 2007. Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK.
Ann. Rheum. Dis.
66: 970–973.
- 150
Franceschini, F. &
I. Cavazzana. 2005. Anti-Ro/SSA and La/SSB antibodies.
Autoimmunity
38: 55–63.
- 151
Shamim, E.A.,
L.G. Rider,
J.P. Pandey,
et al
. 2002. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis.
Arthritis Rheum.
46: 1885–1893.
- 152
Shamim, E.A.,
L.G. Rider &
F.W. Miller. 2000. Update on the genetics of the idiopathic inflammatory myopathies.
Curr. Opin. Rheumatol.
12: 482–491.
- 153
Chinoy, H.,
W.E. Ollier &
R.G. Cooper. 2004. Have recent immunogenetic investigations increased our understanding of disease mechanisms in the idiopathic inflammatory myopathies?
Curr. Opin. Rheumatol.
16: 707–713.
- 154
Mierau, R.,
T. Dick,
E. Genth,
et al
. 1999. An update on HLA association of Mi-2 autoantibodies: the association with a tryptophan at position 9 of the HLA-DRbeta chain is strong but not absolute.
Arthritis Rheum.
42: 1552–1553.
- 155
Stertz, G.
1916. Polymyositis. Berl. Klin. Wochenschr.
53: 489.
- 156
Kankeleit, H.
1916. Uber primaire nichteitrige Polymyositis.
Dtsch. Arch. Klin. Med.
120: 335.
- 157
Williams, R.C., Jr. 1959. Dermatomyositis and malignancy: a review of the literature.
Ann. Intern. Med.
50: 1174–1181.
- 158
Barnes, B.E. &
B. Mawr. 1976. Dermatomyositis and malignancy. A review of the literature.
Ann. Intern. Med.
84: 68–76.
- 159
Sigurgeirsson, B.,
B. Lindelof,
O. Edhag,
et al
. 1992. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study.
N. Engl. J. Med.
326: 363–367.
- 160
Hill, C.L.,
Y. Zhang,
B. Sigurgeirsson,
et al
. 2001. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.
Lancet
357: 96–100.
- 161
Buchbinder, R.,
A. Forbes,
S. Hall,
et al
. 2001. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study.
Ann. Intern. Med.
134: 1087–1095.
- 162
Andras, C.,
A. Ponyi,
T. Constantin,
et al
. 2008. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study.
J. Rheumatol.
35: 438–444.
- 163
Amoura, Z.,
P. Duhaut,
D.L. Huong,
et al
. 2005. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies.
Cancer Epidemiol. Biomarkers Prev.
14: 1279–1282.
- 164
Chinoy, H.,
N. Fertig,
C.V. Oddis,
et al
. 2007. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis.
Ann. Rheum. Dis.
66: 1345–1349.
- 165
Levine, S.M.
2006. Cancer and myositis: new insights into an old association.
Curr. Opin. Rheumatol.
18: 620–624.
- 166
Suber, T.L.,
L. Casciola-Rosen &
A. Rosen. 2008. Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis.
Nat. Clin. Pract. Rheumatol.
4: 201–209.
